Appellate courts issued a variety of notable intellectual property (IP) cases in 2024, including cases touching on Orange Book ...

Desmopressin is approved in various forms, but these do not meet the paediatric need for precise, titratable and small doses.

Stifel analysts have maintained a Buy rating and a $28.00 price target for Phathom Pharmaceuticals (NASDAQ:PHAT), focusing on the company's recent developments. Currently trading at $5.59, ...

Product has patent protection through 2044 - - Expected to be listed in the U.S. Food and Drug Administration’s (FDA) Orange Book upon the ...

Eton Pharmaceuticals (ETON) announced that the United States Patent and Trademark Office has granted the company U.S. Patent No. 12,214,010, ...

Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. For more information on ...

Journey Medical's future hinges on Emrosi, a new formulation of minocycline for rosacea, showing superior efficacy. Read why I rate DERM stock a Buy.

The Food and Drug Administration announced it would decide by April 2024 whether chemical hair straightening products sold in the U.S. would be banned from using formaldehyde or ingredients that ...

This month, the U.S. Food and Drug Administration (FDA) banned the use of the synthetic food dye Red Dye No. 3 in food products. While the discontinuation of the allowance of Red No. 3 is ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...

Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...

Jan 21 (Reuters) - The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's (JNJ.N), opens new tab nasal spray, Spravato, to allow it to be used as a standalone treatment ...